Movano

Movano, Inc. is a health-focused technology company. The firm uses non-invasive technology to enable individuals and their healthcare partners to measure and manage their health conditions. It offers solutions through the app, the cloud, the wearable, and the sensor. The company was founded by Michael Leabman in January 2018 and is headquartered in Pleasanton, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Movano Health reports revenue growth but faces operating loss in Q1 2024

Movano Health's Q1 2024 performance showed revenue from Evie Ring shipments but an operating loss, mitigated by a $24 million private placement. The company aims to optimize operations, secure FDA clearance, and expand partnerships to drive growth and profitability.

Movano Health advances FDA-cleared products, eyes clinical trials for growth

Movano Health's Q2 2024 earnings call highlighted progress, challenges, and opportunities in the health monitoring technology sector. With a focus on product development, marketing strategies, and capital management, Movano aims to drive growth and innovation in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

As the pioneer of the first FDA-approved continuous glucose monitor, Dr. Mastrototaro will be integral in advancing the development and regulatory process of the Company's glucose and blood pressure monitoring technology PLEASANTON, CA / ACCESSWIRE / March 25, 2021 / Today, Movano Inc. (NASDAQ:MOVE), a health technology company designing devices that empower individuals to optimize their health in order to prevent and better manage chronic diseases, announced current Director, Dr. John Mastrototaro, will join the Company as CEO, effective April 1, 2021. Movano's founder and current CEO, Michael Leabman, will become the Company's CTO and will remain on the Company's Board of Directors.

Movano Inc. Appoints Medtech Industry Veteran John Mastrototaro, PhD, as CEO

PLEASANTON, CA / ACCESSWIRE /  March 25, 2021 / Movano Inc. (NASDAQ:MOVE), a health technology company designing devices that empower individuals to optimize their health in order to prevent and better manage chronic diseases, has closed its previously announced initial public offering of 8,500,000 shares of its common stock at a public offering price of $5.00 per share. In connection with the closing of the offering, the underwriter exercised its over-allotment option to purchase an additional 1,275,000 shares in full.

Movano Inc. Announces Closing of Initial Public Offering and Exercise of Over-Allotment Option

News for Movano Stock (MOVE)